Observational study finds hormone therapy users lose 35% more weight than non-users — Evidence Review

A new observational study from the Mayo Clinic suggests that postmenopausal women using hormone therapy experience greater weight loss with tirzepatide than those using the medication alone. Prior research generally finds that hormone therapy alone does not cause significant weight loss, but may modestly impact body composition and fat distribution.

• Most previous studies conclude that hormone therapy does not significantly alter overall body weight in postmenopausal women, but may reduce abdominal fat and prevent some adverse changes in fat distribution associated with menopause 1 6 9 10.
• The observed synergy between hormone therapy and GLP-1-based medications like tirzepatide in the new study expands on earlier indications that estrogen may enhance appetite-suppressing effects of these drugs, an area previously suggested by preclinical data but not yet well-established in humans 4 10.
• The new findings differ from the consensus that hormone therapy alone has little effect on weight, instead highlighting a potential interaction with specific obesity medications that could offer new treatment avenues for postmenopausal women 1 6 9.

Study Overview and Key Findings

Weight gain and increased cardiometabolic risk are common concerns for women after menopause. This study is timely as it explores whether combining established menopause symptom management (hormone therapy) with emerging, highly effective weight-loss medications could yield additional health benefits. Notably, while hormone therapy is widely used to manage hot flashes and night sweats, its direct impact on weight has been uncertain. By focusing on the combination of hormone therapy and tirzepatide in postmenopausal women with overweight or obesity, this study investigates a potentially important interaction that could inform more personalized and effective obesity treatment strategies for this population.

Property	Value
Study Year	2026
Organization	Mayo Clinic
Journal Name	The Lancet Obstetrics, Gynaecology, & Women’s Health
Authors	Regina Castaneda, Dima Bechenati, Elif Tama, Rene Rivera Gutierrez, Maria A Espinosa, Jose Villamarin, Tamim I Rajjo, Andres Acosta, Stephanie Faubion, Chrisandra Shufelt, Maria D Hurtado Andrade
Population	Postmenopausal women with overweight or obesity
Sample Size	n=120
Methods	Observational Study
Outcome	Weight loss comparison between hormone therapy users and non-users
Results	Hormone therapy users lost about 35% more weight than non-users.

Literature Review: Related Studies

To contextualize these findings, we searched the Consensus database, which contains over 200 million research papers, for relevant studies on hormone therapy, weight loss, and obesity. The following search queries were used:

1. hormone therapy weight loss comparison
2. weight loss outcomes hormone therapy users
3. effects of hormone therapy on obesity

Topic	Key Findings
Does hormone therapy affect weight, fat distribution, or muscle mass in postmenopausal women?	- Most randomized controlled trials (RCTs) and systematic reviews find no significant effect of hormone therapy on overall weight gain or loss in postmenopausal women 1 6. - Hormone therapy may modestly reduce abdominal fat accumulation and improve fat distribution, but effects on muscle mass are minimal or not significant 3 9 10.
What is the efficacy and mechanism of GLP-1/GIP-based medications like tirzepatide for weight loss?	- GLP-1 receptor agonists and dual agonists such as tirzepatide lead to substantial weight loss and improvements in cardiometabolic risk factors, with efficacy approaching that of bariatric surgery in some trials 4. - Preclinical data suggest estrogen may enhance the appetite-suppressing effects of GLP-1, but human data are limited 10.
Are there synergistic effects between hormone therapy and anti-obesity medications?	- Direct evidence for synergy is limited, but some animal and early human studies suggest estrogens could enhance the efficacy of GLP-1-based therapies by modulating appetite and energy balance 4 10. - The new Mayo Clinic study is among the first to directly report greater weight loss with combined therapy in postmenopausal women.
Does hormone therapy impact other health outcomes, such as metabolic syndrome or body composition?	- Hormone therapy may improve insulin sensitivity and reduce the risk of type 2 diabetes, though effects on body composition and metabolic syndrome are generally modest 3 9. - Effects on lean body mass are minimal, and benefits may depend on individual risk factors and lifestyle behaviors 3 6 9.

Does hormone therapy affect weight, fat distribution, or muscle mass in postmenopausal women?

Prior studies consistently show that hormone therapy does not significantly alter overall body weight in postmenopausal women, although it may help prevent menopause-related increases in abdominal adiposity and may slightly attenuate weight gain. Effects on muscle mass are minimal and generally not clinically significant.

• Systematic reviews and randomized trials report no statistically significant difference in mean weight gain or BMI between hormone therapy users and non-users 1 6.
• Some studies indicate hormone therapy may reduce increases in abdominal fat and improve fat distribution, with possible improvements in insulin sensitivity 9 10.
• Meta-analyses find no significant impact on muscle mass or lean body mass, suggesting hormone therapy should not be relied upon for muscle preservation 3.
• Lifestyle factors, such as physical activity and diet, remain important determinants of weight trajectory in postmenopausal women 6 9.

What is the efficacy and mechanism of GLP-1/GIP-based medications like tirzepatide for weight loss?

GLP-1 receptor agonists and dual agonists, such as tirzepatide, represent a major advancement in obesity pharmacotherapy, offering significant and sustained weight loss and cardiometabolic benefits. Some preclinical data suggest potential interactions between estrogen and GLP-1 pathways.

• Tirzepatide and similar agents can achieve weight loss approaching or exceeding 20% in clinical trials, with additional benefits for glycemic control and cardiometabolic risk factors 4.
• GLP-1-based medications act through appetite suppression and modulation of energy balance, with some evidence that estrogens may enhance these effects via central mechanisms 10.
• The new study's finding of greater weight loss with hormone therapy plus tirzepatide is consistent with preclinical suggestions of a synergistic effect, but human evidence has been sparse 4 10.
• Future research is needed to clarify the biological mechanisms and clinical relevance of these potential interactions 4 10.

Are there synergistic effects between hormone therapy and anti-obesity medications?

Direct evidence for synergy between hormone therapy and GLP-1-based medications is limited, but animal studies and emerging human data suggest the possibility of enhanced effects when these treatments are combined.

• Preclinical studies highlight that estrogen may potentiate the appetite-suppressing effects of GLP-1, potentially leading to greater weight loss 10.
• The Mayo Clinic study is among the first to systematically compare weight loss outcomes in women receiving both hormone therapy and tirzepatide, finding a 35% greater reduction in weight among hormone therapy users.
• Prior clinical trials focused on hormone therapy alone have not reported significant weight loss, underscoring the novelty of the observed interaction 1 6 9.
• Further randomized trials are needed to confirm causality and explore mechanisms underlying this observed synergy.

Does hormone therapy impact other health outcomes, such as metabolic syndrome or body composition?

Hormone therapy may offer modest benefits for metabolic health and fat distribution, though effects on body weight and muscle mass are limited. Benefits may be more pronounced in specific subgroups or in combination with other interventions.

• Several reviews and trials indicate hormone therapy can improve insulin sensitivity and reduce incidence of type 2 diabetes, possibly through shifts in fat distribution 9.
• Effects on lean body mass are not significant, and hormone therapy alone does not prevent age-related loss of muscle mass 3 6.
• The interaction with anti-obesity medications may open new avenues for improving cardiometabolic risk, but requires further study 4 10.
• Individual responses to hormone therapy may depend on baseline characteristics such as age, weight, and lifestyle factors 6 9.

Future Research Questions

While the new study raises the possibility of a biological synergy between hormone therapy and GLP-1-based obesity medications, its observational design limits causal interpretations. There is a need for prospective, randomized trials to confirm these findings and to better understand the mechanisms involved. Additionally, the long-term safety, metabolic effects, and applicability across diverse subgroups remain to be clarified.

Research Question	Relevance
Does hormone therapy causally enhance weight loss with GLP-1-based medications in postmenopausal women?	Randomized trials are needed to determine whether the observed association is causal and to quantify the true effect size, building on the initial observational evidence 4 10.
What are the mechanisms underlying the potential synergy between estrogen and GLP-1 signaling?	Understanding the biological pathways could inform the development of more effective, tailored obesity therapies for postmenopausal women 4 10.
Do the cardiometabolic benefits of combined hormone therapy and GLP-1 agonists extend beyond weight loss?	It is important to assess whether the combination improves outcomes such as blood pressure, glucose metabolism, and cardiovascular risk beyond weight reduction alone 4 9.
How do lifestyle factors interact with hormone therapy and GLP-1-based weight loss treatments?	Lifestyle behaviors may modify treatment response and should be considered in the design of future studies and in clinical practice 6 9.
Are there differences in effectiveness or safety of the combination treatment across different populations or demographic groups?	Understanding subgroup effects will help tailor treatment recommendations and ensure safety and efficacy for diverse patient populations 6 9.